The global red biotechnology market size is expected to reach USD 997.74 billion by 2030 expanding at a CAGR of 10.6% from 2023 to 2030. Red biotechnology has emerged as a most dynamic fields in terms of innovation in past few years. With increasing burden of chronic illnesses such as cancers, genetic disorders, diabetes, and many more, the demand for vaccines, monoclonal antibodies, gene therapies, and cell therapies has grown significantly. Robust pipeline is also expected to propel the growth of red biotechnology market on account of number of expected regulatory approvals in coming years.
COVID- 19 pandemic also had a positive impact on the global market. The approval of various vaccines for management of the virus injected huge revenues within the market place. Similarly enormous number of research studies done for mapping the virus and formulating the vaccine resulted in an increased demand for antibodies, recombinant proteins, enzymes, and many more. For instance, in May 2022, Bharat Biotech received a funding of USD 19 million from Coalition for Epidemic Preparedness Innovations to develop variant proof vaccine against the COVID-19 virus. The pandemic also marked entry of huge number of startups pertaining to biotechnology space creating new market opportunities in emerging countries.
The biotechnology industry is being impacted by Artificial Intelligence (AI), which is important for many processes involved in creating alternative treatments. In the process of developing new medications, artificial intelligence and machine learning are routinely used now. Machine learning makes it easier to find small compounds with medicinal potential based on known target architectures. Increasing adoption of AI in clinical and preclinical studies is expected to reduce the time required to carry out these studies, which in turn is expected to increase the demand for red biotechnology subsets in coming years.
This product will be delivered within 1-3 business days.
COVID- 19 pandemic also had a positive impact on the global market. The approval of various vaccines for management of the virus injected huge revenues within the market place. Similarly enormous number of research studies done for mapping the virus and formulating the vaccine resulted in an increased demand for antibodies, recombinant proteins, enzymes, and many more. For instance, in May 2022, Bharat Biotech received a funding of USD 19 million from Coalition for Epidemic Preparedness Innovations to develop variant proof vaccine against the COVID-19 virus. The pandemic also marked entry of huge number of startups pertaining to biotechnology space creating new market opportunities in emerging countries.
The biotechnology industry is being impacted by Artificial Intelligence (AI), which is important for many processes involved in creating alternative treatments. In the process of developing new medications, artificial intelligence and machine learning are routinely used now. Machine learning makes it easier to find small compounds with medicinal potential based on known target architectures. Increasing adoption of AI in clinical and preclinical studies is expected to reduce the time required to carry out these studies, which in turn is expected to increase the demand for red biotechnology subsets in coming years.
Red Biotechnology Market Report Highlights
- By product, the monoclonal antibody is considered to be a relatively more mature and dominant segment compared to other products in the red biotechnology market. Increasing sales and improved efficacy of these drugs are the major reason for the segment dominant. Large number of drug approvals in past years has resulted in huge revenue generation.
- By end-user, the pharmaceutical & biotechnology companies accounted for majority of revenue in the red biotechnology industry. Increasing number of clinical trials being performed by the companies, growth in R&D and robust pipeline is expected to be the major factors effecting the revenue growth of the segment
- North America has emerged a strong regional position in the market with 38.07% share of the overall market in 2022. The increasing incidence rate of cancer and high R&D expenditure are encouraging companies to undertake product development in the region.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing R&D funding in the biotechnology industry.
3.4.2. Rising prevalence of chronic diseases.
3.4.3. Technological advancements across multiple platforms
3.4.4. Declining prices of DNA sequencing
3.5. Market Restraint Analysis
3.5.1. High level of investment in developing technologically advanced products
3.5.2. Ethical & legal limitations
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Red Biotechnology Market: Product Movement Analysis
4.2. Monoclonal Antibodies
4.2.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Billion)
4.3. Polyclonal Antibodies
4.3.1. Polyclonal Antibodies Market, 2018 - 2030 (USD Billion)
4.4. Recombinant Proteins
4.4.1. Recombinant Proteins Market, 2018 - 2030 (USD Billion)
4.5. Vaccines
4.5.1. Vaccines Market, 2018 - 2030 (USD Billion)
4.6. Cell-Based Immunotherapy Products
4.6.1. Cell-Based Immunotherapy Products Market, 2018 - 2030 (USD Billion)
4.7. Gene Therapy Products
4.7.1. Gene Therapy Products Market, 2018 - 2030 (USD Billion)
4.8. Cell Therapy Products
4.8.1. Cell Therapy Products Market, 2018 - 2030 (USD Billion)
4.9. Tissue-Engineered Products
4.9.1. Tissue-Engineered Products Market, 2018 - 2030 (USD Billion)
4.10. Stem Cells
4.10.1. Stem Cells Market, 2018 - 2030 (USD Billion)
4.11. Cell Culture
4.11.1. Cell Culture Market, 2018 - 2030 (USD Billion)
4.12. Viral Vector
4.12.1. Viral Vector Market, 2018 - 2030 (USD Billion)
4.13. Enzymes
4.13.1. Enzymes Market, 2018 - 2030 (USD Billion)
4.14. Kits and Reagents
4.14.1. Kits and Reagents Market, 2018 - 2030 (USD Billion)
4.15. Animal Models
4.15.1. Animal Models Market, 2018 - 2030 (USD Billion)
4.16. Molecular Diagnostics
4.16.1. Molecular Diagnostics Market, 2018 - 2030 (USD Billion)
4.17. Others
4.17.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 5. End-User Business Analysis
5.1. Red Biotechnology Market: End-User Movement Analysis
5.2. Academic Research Institutes
5.2.1. Academic Research Institutes Market, 2018 - 2030 (USD Billion)
5.3. CMOs & CROs
5.3.1. CMOs & CROs Market, 2018 - 2030 (USD Billion)
5.4. Pharmaceutical & Biotechnology Companies
5.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Billion)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 6. Regional Business Analysis
6.1. Red Biotechnology Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. SWOT Analysis
6.2.2. North America red biotechnology market, 2018 - 2030 (USD Billion)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. U.S. red biotechnology market, 2018 - 2030 (USD Billion)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Canada red biotechnology market, 2018 - 2030 (USD Billion)
6.3. Europe
6.3.1. SWOT Analysis
6.3.2. Europe red biotechnology market, 2018 - 2030 (USD Billion)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Germany red biotechnology market, 2018 - 2030 (USD Billion)
6.3.4. U.K.
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. U.K. red biotechnology market, 2018 - 2030 (USD Billion)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. France red biotechnology market, 2018 - 2030 (USD Billion)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Italy red biotechnology market, 2018 - 2030 (USD Billion)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Spain red biotechnology market, 2018 - 2030 (USD Billion)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Denmark red biotechnology market, 2018 - 2030 (USD Billion)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Sweden red biotechnology market, 2018 - 2030 (USD Billion)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Norway red biotechnology market, 2018 - 2030 (USD Billion)
6.4. Asia Pacific
6.4.1. SWOT Analysis
6.4.2. Asia Pacific red biotechnology market, 2018 - 2030 (USD Billion)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Japan red biotechnology market, 2018 - 2030 (USD Billion)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. China red biotechnology market, 2018 - 2030 (USD Billion)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. India red biotechnology market, 2018 - 2030 (USD Billion)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. South Korea red biotechnology market, 2018 - 2030 (USD Billion)
6.4.7. Australia
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Australia red biotechnology market, 2018 - 2030 (USD Billion)
6.4.8. Thailand
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. Thailand red biotechnology market, 2018 - 2030 (USD Billion)
6.5. Latin America
6.5.1. SWOT Analysis
6.5.2. Latin America red biotechnology market, 2018 - 2030 (USD Billion)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Brazil red biotechnology market, 2018 - 2030 (USD Billion)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Mexico red biotechnology market, 2018 - 2030 (USD Billion)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Argentina red biotechnology market, 2018 - 2030 (USD Billion)
6.6. MEA
6.6.1. SWOT Analysis
6.6.2. MEA red biotechnology market, 2018 - 2030 (USD Billion)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. South Africa red biotechnology market, 2018 - 2030 (USD Billion)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Saudi Arabia red biotechnology market, 2018 - 2030 (USD Billion)
6.6.5. UAE
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. UAE red biotechnology market, 2018 - 2030 (USD Billion)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Kuwait red biotechnology market, 2018 - 2030 (USD Billion)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Company Market Share Analysis, 2022
7.3. Strategy Mapping
7.4. Company Profiles/Listing
7.4.1. Merck KGaA
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Hoffmann-La Roche, Ltd.
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Pfizer Inc.
7.4.3.1. Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Regeneron Pharmaceuticals, Inc.
7.4.4.1. Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. AstraZeneca Plc.
7.4.5.1. Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Takeda Pharmaceutical Company Limited
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Gilead Sciences
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Biogen Inc.
7.4.8.1. Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Amgen Inc.
7.4.9.1. Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Celgene Corporation
7.4.10.1. Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
TABLE 2. List of Abbreviations
TABLE 3. Global red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 4. Global red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 5. Global red biotechnology market, by Region, 2018 - 2030 (USD Billion)
TABLE 6. North America red biotechnology market, by country, 2018 - 2030 (USD Billion)
TABLE 7. North America red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 8. North America red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 9. U.S. red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 10. U.S. red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 11. Canada red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 12. Canada red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 13. Europe red biotechnology market, by country, 2018 - 2030 (USD Billion)
TABLE 14. Europe red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 15. Europe red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 16. U.K. red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 17. Europe red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 18. Germany red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 19. Germany red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 20. France red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 21. France red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 22. Italy red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 23. Italy red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 24. Spain red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 25. Spain red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 26. Denmark red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 27. Denmark red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 28. Sweden red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 29. Sweden red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 30. Norway red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 31. Norway red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 32. Asia Pacific red biotechnology market, by country, 2018 - 2030 (USD Billion)
TABLE 33. Asia Pacific red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 34. Asia Pacific red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 35. Japan red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 36. Japan red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 37. China red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 38. China red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 39. India red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 40. India red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 41. Australia red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 42. Australia red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 43. Thailand red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 44. Thailand red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 45. South Korea red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 46. South Korea red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 47. Latin America red biotechnology market, by country, 2018 - 2030 (USD Billion)
TABLE 48. Latin America red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 49. Latin America red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 50. Brazil red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 51. Brazil red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 52. Mexico red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 53. Mexico red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 54. Argentina red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 55. Argentina red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 56. Middle East and Africa red biotechnology market, by country, 2018 - 2030 (USD Billion)
TABLE 57. Middle East and Africa red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 58. Middle East and Africa red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 59. South Africa red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 60. South Africa red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 61. Saudi Arabia red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 62. Saudi Arabia red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 63. UAE red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 64. UAE red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
TABLE 65. Kuwait red biotechnology market, by product, 2018 - 2030 (USD Billion)
TABLE 66. Kuwait red biotechnology market, by end-user, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain-Based Sizing & Forecasting
FIG. 6 Market Formulation & Validation
FIG. 7 Red biotechnology market Segmentation
FIG. 8 Market Snapshot, 2022
FIG. 9 Market Trends & Outlook
FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 12 Market Challenge Relevance Analysis (Current & Future Impact)
FIG. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Market Penetration Vs Growth Prospect Mapping, 2022
FIG. 16 Global Red biotechnology market: Product Movement Analysis
FIG. 17 Global red biotechnology market, for Monoclonal Antibodies, 2018 - 2030 (USD Billion)
FIG. 18 Global red biotechnology market, for Polyclonal Antibodies, 2018 - 2030 (USD Billion)
FIG. 19 Global red biotechnology market, for Recombinant Proteins, 2018 - 2030 (USD Billion)
FIG. 20 Global red biotechnology market, for Vaccines, 2018 - 2030 (USD Billion)
FIG. 21 Global red biotechnology market, for Cell-Based Immunotherapy Products, 2018 - 2030 (USD Billion)
FIG. 22 Global red biotechnology market, for Gene Therapy Products, 2018 - 2030 (USD Billion)
FIG. 23 Global red biotechnology market, for Cell Therapy Products, 2018 - 2030 (USD Billion)
FIG. 24 Global red biotechnology market, for Tissue-Engineered Products, 2018 - 2030 (USD Billion)
FIG. 25 Global red biotechnology market, for Stem Cells, 2018 - 2030 (USD Billion)
FIG. 26 Global red biotechnology market, for Cell Culture, 2018 - 2030 (USD Billion)
FIG. 27 Global red biotechnology market, for Viral Vector, 2018 - 2030 (USD Billion)
FIG. 28 Global red biotechnology market, for Enzymes, 2018 - 2030 (USD Billion)
FIG. 29 Global red biotechnology market, for Kits and Reagents, 2018 - 2030 (USD Billion)
FIG. 30 Global red biotechnology market, for Animal Models, 2018 - 2030 (USD Billion)
FIG. 31 Global red biotechnology market, for Molecular Diagnostics, 2018 - 2030 (USD Billion)
FIG. 32 Global red biotechnology market, for Others, 2018 - 2030 (USD Billion)
FIG. 33 Global Red biotechnology market: End-user Movement Analysis
FIG. 34 Global red biotechnology market, for Academic Research Institutes, 2018 - 2030 (USD Billion)
FIG. 35 Global red biotechnology market, for CMOs & CROs, 2018 - 2030 (USD Billion)
FIG. 36 Global red biotechnology market, for Pharmaceutical & Biotechnology Companies, 2018 - 2030 (USD Billion)
FIG. 37 Global red biotechnology market, for Others, 2018 - 2030 (USD Billion)
FIG. 38 Regional Marketplace: Key Takeaways
FIG. 39 Regional Outlook, 2022 & 2030
FIG. 40 Global Red biotechnology market: Region Movement Analysis
FIG. 41 North America red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 42 U.S. red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 43 Canada red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 44 Europe red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 45 Germany red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 46 U.K. red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 47 France red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 48 Italy red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 49 Spain red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 50 Denmark red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 51 Sweden red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 52 Norway red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 53 Asia Pacific red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 54 Japan red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 55 China red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 56 India red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 57 Australia red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 58 South Korea red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 59 Thailand red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 60 Latin America red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 61 Brazil red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 62 Mexico red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 63 Argentina red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 64 Middle East and Africa red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 65 South Africa red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 66 Saudi Arabia red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 67 UAE red biotechnology market, 2018 - 2030 (USD Billion)
FIG. 68 Kuwait red biotechnology market, 2018 - 2030 (USD Billion)
Companies Mentioned
- Merck KGaA
- Hoffmann-La Roche, Ltd.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- AstraZeneca Plc.
- Takeda Pharmaceutical Company Limited
- Gilead Sciences
- Biogen Inc.
- Amgen Inc.
- Celgene Corporation
Methodology
LOADING...
